{
    "clinical_study": {
        "@rank": "107562", 
        "arm_group": [
            {
                "arm_group_label": "Walnuts", 
                "arm_group_type": "Experimental", 
                "description": "This group will receive one ounce of walnuts per day"
            }, 
            {
                "arm_group_label": "Usual diet (no walnuts)", 
                "arm_group_type": "No Intervention", 
                "description": "Control group (does not receive walnuts in the diet)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will examine whether a twelve-week intervention with one ounce (28 g) per day of\n      walnuts improves endothelial function measured non-invasively using finger probe\n      (EndoPat-2000) in people with coronary heart disease or type 2 diabetes."
        }, 
        "brief_title": "Walnut Consumption, Endothelial Function, and Biomarkers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Heart Disease", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Heart Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 30+ years\n\n          -  Prevalent coronary artery disease\n\n          -  Prevalent type 2 diabetes\n\n        Exclusion Criteria:\n\n          -  Current eating disorder\n\n          -  Pregnant or lactating women\n\n          -  Allergy to walnuts or other nuts\n\n          -  Inability to provide informed consent or blood samples\n\n          -  History or prevalent diagnosis of cancer, asthma, kidney insufficiency, stroke,\n             seizures, allergic disorders, or congestive heart failure\n\n          -  Diagnosis of coronary heart disease or diabetes < 1 year prior to enrollment\n\n          -  Intention to move out of greater Boston area within one year\n\n          -  Current use of walnuts for more than 2 ounces per day\n\n          -  Bleeding disorder\n\n          -  Treatment with blood thinning drugs (i.e. warfarin, clopidogrel)\n\n          -  Major surgical operation 3 months before or after screening\n\n          -  Organ transplantation\n\n          -  Current participation in another trial or plan to do so during the study\n\n          -  Use of vasodilators such as nitroglycerin\n\n          -  Inability to give informed consent\n\n          -  Inability to travel to the study center at Brigham and Women's Hospital"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884363", 
            "org_study_id": "2013P000803"
        }, 
        "intervention": {
            "arm_group_label": "Walnuts", 
            "intervention_name": "Once ounce per day of walnuts", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endothelial function", 
            "walnuts", 
            "clinical trial", 
            "Nutrition", 
            "cardiovascular disease"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "ldjousse@partners.org", 
                "last_name": "Luc Djousse, MD, ScD", 
                "phone": "617-525-7591"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02120"
                }, 
                "name": "Brigham and Women's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Walnut Consumption, Endothelial Function, and Plasma Adipokines in Subjects With Diabetes or Coronary Disease: a Pilot Trial", 
        "other_outcome": {
            "description": "Change in heart rate variability will be measured in each group before and after 12 weeks.", 
            "measure": "Change in heart rate variability between baseline and 12 weeks post-intervention", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "email": "ldjousse@partners.org", 
            "last_name": "Luc Djousse, MD, ScD", 
            "phone": "617-525-7591"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Luc Djousse, MD, ScD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reactive hyperemia index (RHI), which in part reflects vasodilator function of the small blood vessel at the fingertips is an indirect measure of endothelial function. Change in RHI between baseline and 12 weeks post intervention will be measured in each group using EndoPat2000 device. We will compare RHI change between walnut group and usual diet group.", 
            "measure": "Change in reactive hyperemia index occurring between baseline and 12 weeks (end of intervention)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884363"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Luc Djousse", 
            "investigator_title": "Director of Research, Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Specifically, we will measure changes in blood levels of following hormones: retinol binding protein 4, fatty acid binding protein 4, total adiponectin, and leptin before and after 12 weeks of walnut consumption/consumption of usual diet.", 
            "measure": "Change in blood levels of hormones produced by fat cells between baseline and 12 weeks (end of intervention)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}